SCHEDULE 13G/A: EcoR1 Capital Divests Entire Stake in Mersana Therapeutics, Filing Shows 0% Beneficial Ownership

Sentiment:

Beneficial Ownership Change 15 May 2025 6:16 PM

📋All filings for Mersana Therapeutics, INC

Investment firm EcoR1 Capital, LLC and its affiliates have reported a 0% beneficial ownership stake in Mersana Therapeutics, Inc., indicating a complete divestment or reduction below the reporting threshold.

Worse than expectedThe reporting persons, EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman, previously held a reportable stake in Mersana Therapeutics, Inc. and have now reported 0% beneficial ownership, indicating a complete divestment or reduction below the 5% reporting threshold, which is generally perceived negatively by the market.

Summary

EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have filed an Amendment No. 2 to Schedule 13G for Mersana Therapeutics, Inc.
The filing indicates that the reporting persons now beneficially own 0% of Mersana Therapeutics' Common Stock.
This suggests a complete divestment of their previous stake or a reduction below the 5% reporting threshold that requires Schedule 13G filing.
The CUSIP number for Mersana Therapeutics, Inc. Common Stock is 59045L106.
The event date requiring this filing, when beneficial ownership fell below the reporting threshold, was March 31, 2025.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment by EcoR1 Capital and its affiliates, which can be interpreted as a negative signal regarding their outlook on Mersana Therapeutics, Inc.

Future Outlook

Management Comments

The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a change in an institutional investor's position in a biotechnology/pharmaceutical company. Such divestments can sometimes signal a change in investor sentiment towards the company or the sector, though the filing itself provides no reason for the divestment.

Stakeholder Impact

Shareholders: Potential negative sentiment due to a significant institutional investor divesting its entire stake, which could lead to downward pressure on the stock price.

Key Dates

Date	Description
03/31/2025	Date of event requiring the filing of this statement, indicating the point at which beneficial ownership fell below the reporting threshold.
05/15/2025	Signature date of the Schedule 13G Amendment No. 2 filing.

Recommendation

sell

Keywords

Mersana Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, beneficial ownership, divestment, common stock, investment firm

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.